GH secretagogues and uses thereof
View Patent ↗The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
1. A method of treating HIV-related lipodystrophy in a subject in need thereof, without a significant impairment of glucose control and with a decrease in (a) total cholesterol, (b) non-HDL cholesterol, or (c), both (a) and (b), said method comprising administering to said subject (i) (hexenoyl trans-3)hGRF(1-44)NH 2 , or
(ii) a composition comprising said (hexenoyl trans-3)hGRF(1-44)NH 2 and a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein said subject is receiving antiviral therapy.
3. The method of claim 1 , wherein said subject also suffers from diabetes, glucose intolerance or insulin resistance.
4. The method of claim 1 , wherein said (hexenoyl trans-3)hGRF(1-44) NH 2 is administered at a dose of about 1 mg or about 2 mg.
5. The method of claim 1 , wherein said (hexenoyl trans-3)hGRF(1-44) NH 2 or said composition is administered by an intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal or topical route.
6. The method of claim 5 , wherein said (hexenoyl trans-3)hGRF(1-44) NH 2 or said composition is administered by a subcutaneous route.
7. The method of claim 4 , wherein said (hexenoyl trans-3)hGRF(1-44) NH 2 is administered at a dose of about 2 mg.
8. The method of claim 1 , wherein said method is with a decrease in total cholesterol.
9. The method of claim 1 , wherein said method is with a decrease in non-HDL cholesterol.
10. The method of claim 1 , wherein said method is with a decrease in both total cholesterol and non-HDL cholesterol.